Pharmaceuticals

B. Braun has been owned and run by the same family since 1839 — five generations, surviving two world wars, the Weimar hyperinflation, and the Nazi era, without ever losing control of the company. It started as a tiny pharmacy in Melsungen, a town of a few thousand people, where founder Julius Wilhelm Braun compounded medicines himself; today it is one of the world's largest medical technology companies. The company's product range covers the entire hospital supply chain: infusion pumps and IV solutions (its original specialty), syringes and needles, surgical instruments, wound care dressings, and hospital disinfectants. Braun is the global leader in several of these niches — its Braunüle IV catheters and its infusion systems are standard equipment in operating rooms and ICUs on every continent. With about 63,000 employees and annual revenue near €8.8 billion, Braun operates in 60+ countries and remains remarkably true to its roots: headquarters still in Melsungen (population 13,000), still family-owned, still reinvesting heavily in R&D. For hospitals and healthcare distributors, Braun is the dependable German supplier — not the flashiest brand, but the one whose products clinicians trust without thinking.

Medtronic's founding story is medical-device legend: in 1949, electrical engineer Earl Bakken started repairing medical equipment in a Minneapolis garage, and in 1957 — after a power outage disabled a hospital's bulky external pacemaker and a child died — he built the first battery-powered, wearable pacemaker using metronome circuits. That device launched the modern medical device industry, and the company he co-founded is now the world's largest. The product range spans nearly every medical specialty: cardiac devices (pacemakers, defibrillators, and the LINQ insertable monitors), diabetes management (insulin pumps and continuous glucose monitors), surgical robotics (the Hugo system), spinal and orthopedic implants, and minimally invasive surgical instruments. Medtronic's devices are used in virtually every hospital in the developed world, and its R&D budget of over US$2.5 billion a year keeps the pipeline full. Legally headquartered in Dublin (with operational headquarters in Minneapolis), Medtronic employs about 95,000 people and generates annual revenue near US$32 billion. Its scale makes it both the industry's benchmark and its consolidator — dozens of innovative startups have been absorbed into Medtronic's portfolio, a pattern that defines how medical technology reaches patients at scale.

Roche was founded in 1896 in Basel by Fritz Hoffmann-La Roche, who bet on a business model that was radical at the time: producing standardized medicines in factories instead of mixing them in pharmacies. The company's first hit was a cough syrup; its first blockbuster was a vitamin product in the 1930s; and its modern identity was forged in the 1960s with the discovery of Valium — the most prescribed drug in the world at the time. Today Roche is the world's largest biotech company and a leader in oncology: its cancer drugs — including Herceptin, Avastin, and the immunotherapy Tecentriq — have treated millions of patients, and its Hemlibra transformed hemophilia care. Uniquely among pharma giants, Roche is equally powerful in diagnostics: its cobas analyzers and PCR tests run in hospital labs worldwide, and its rapid COVID-19 tests during the pandemic made it a household name. This pharma-plus-diagnostics combination — pairing therapy with the tests that identify who needs it — is Roche's signature strategy. With about 100,000 employees and annual revenue near CHF 60 billion (US$67 billion), Roche is a majority owner of Genentech, the US biotech pioneer, giving it a deep pipeline in gene therapy and personalized medicine. Its biggest challenge is the patent cliff — several blockbusters face biosimilar competition — but its diagnostics franchise and oncology pipeline keep the Swiss giant among the world's most valuable healthcare companies.

Novartis was created in 1996 by the merger of two Swiss pharmaceutical dynasties, Ciba-Geigy and Sandoz — both of which traced their roots to dye factories in the 1850s Basel chemical industry. The name was coined from the Latin 'novae artes', meaning 'new skills', signaling a fresh start for a company with an unusually deep European pedigree. The company's modern focus is prescription medicines across four therapeutic areas: cardiovascular, renal and metabolic (its heart failure drug Entresto and cholesterol treatment Leqvio); immunology (the blockbuster psoriasis and arthritis drug Cosentyx); neuroscience (the schizophrenia treatment and the Alzheimer's drug Leqembi, developed with Eisai); and oncology (the targeted cancer drugs Kisqali and Pluvicto). Its cell and gene therapy division pioneered CAR-T cancer treatments like Kymriah, which engineers a patient's own immune cells to attack tumors. Headquartered in Basel with about 76,000 employees and annual revenue near US$52 billion, Novartis has deliberately streamlined itself — selling its generics business Sandoz in 2023 and its eye care unit — to become a pure innovative medicines company. With one of the industry's deepest pipelines, the 25-year-old company built on 170-year-old roots is a pillar of the global pharma landscape.

Novo Nordisk was born from a Nordic biotech lineage that begins in 1923, when Danish Nobel laureate August Krogh returned from a US lecture tour with a license to produce insulin — making Denmark one of the first countries to treat diabetes domestically. The company formed through a 1989 merger of two Danish insulin makers, Novo and Nordisk, and spent a century perfecting one product category: diabetes care. That single-minded focus paid off spectacularly. Novo's modern pipeline produced semaglutide, marketed as Ozempic (for diabetes) and Wegovy (for obesity) — a GLP-1 drug that has become the best-selling medicine in history, with demand so explosive that Novo has outgrown its entire home country's workforce capacity. Its insulin portfolio (modern insulins and the smart pens that deliver them) still leads the world, and its obesity franchise has turned Novo into Europe's most valuable company, worth more than the entire Danish economy's GDP. Headquartered in Bagsværd, Denmark, with about 65,000 employees and annual revenue near US$34 billion, Novo is majority-owned by the Novo Nordisk Foundation — a unique structure where the charitable foundation reinvests dividends into science. The company's challenge now is keeping up with demand: it is spending billions on new factories in Denmark, France, and the US, racing to produce enough of the weight-loss drug that reshaped global pharma.

AstraZeneca is one of the world's largest biopharmaceutical companies, created in 1999 by the merger of Sweden's Astra AB and the UK's Zeneca Group, and headquartered in Cambridge, England. The company employs about 90,000 people and generates annual revenue of roughly US$45 billion, with three therapeutic pillars: oncology, cardiovascular/renal/metabolic disease, and respiratory & immunology.\n\nAstraZeneca's oncology franchise is anchored by Tagrisso (osimertinib) for EGFR-mutated lung cancer, Imfinzi (durvalumab) for immunotherapy, and Enhertu, a breakthrough antibody-drug conjugate developed with Daiichi Sankyo that is reshaping breast-cancer treatment. The company also built a global vaccines business through the COVID-19 pandemic, developing one of the first widely deployed vaccines with the University of Oxford, and maintains manufacturing sites across the UK, Sweden, the United States, China, and Singapore.\n\nFor pharmaceutical supply chains, AstraZeneca is a major buyer of active pharmaceutical ingredients, biologics raw materials, glass vials, and packaging, with stringent GMP standards, and its global manufacturing network creates stable, long-term procurement demand for specialty chemical and life-science suppliers.

CSL is a global biotechnology company headquartered in Melbourne, Australia, and one of the world's largest producers of plasma-derived and recombinant therapies. Founded in 1916 as the Commonwealth Serum Laboratories, CSL has grown into a USD 13 billion revenue company with operations in more than 35 countries and manufacturing facilities across Australia, the US, Europe and Asia. The company's CSL Behring division is a world leader in plasma therapies for immunology, haematology, critical care and infectious disease, while CSL Seqirus is a top global influenza vaccine manufacturer, and CSL Vifor focuses on iron deficiency and nephrology. CSL operates one of the world's largest plasma collection networks, with over 300 collection centres. For B2B buyers, CSL supplies plasma-derived therapies, vaccines and specialty pharmaceuticals to hospitals, distributors and government health programs worldwide. Its manufacturing excellence, regulatory track record and R&D pipeline make it a critical partner in the global biopharmaceutical supply chain.